^
    9ms
    ASPIRE: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=600, Recruiting, Panbela Therapeutics, Inc. | N=150 --> 600 | Trial completion date: May 2024 --> Jan 2027 | Trial primary completion date: May 2024 --> Aug 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • ivospemin (SBP-101)
    1year
    Effect of Ivospemin and Difluoromethylornithine Polyamine Inhibitors on Viability of Myeloma Cell Lines (ASH 2023)
    The polyamine inhibitors,Ivospemin and DFMO, exhibited a marked anti-proliferative effect in the four human MM cell lines studied when used alone or in combination. These results confirm the anti-neoplastic potential of SBP-101 and DFMO and offer a compelling rationale for its clinical development as a potentially promising treatment option for multiple myeloma. Fig.
    Preclinical
    |
    ANXA5 (Annexin A5)
    |
    ivospemin (SBP-101)